Koselugo (selumetinib), newly approved treatment of neurofibromatosis type 1 (NF1)
13 Aprile 2020
The FDA has approved Koselugo (selumetinib) for the treatment of pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1), a genetic
